| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1626c6ec7ec4e8c1ff68d35b477d4ebf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd8e032d570a5b66c7a95090228d9385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_840e3673e962dde3e5975e5c8d3483a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2610b016ffcdca5f96178baaacba926b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_441f47d96a98e48c940397e2c8a45021 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2004-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bda5e8c085a6b41338fa42003a470b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76592f857c0818a7173c4ab3d25537b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68ba82dfa545ee4e61a5b582948a591a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7948af336e2f2b986621a7c6e4a4af54 |
| publicationDate |
2006-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006018674-A1 |
| titleOfInvention |
Tr1 cells for use in atherosclerosis |
| abstract |
The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2493869-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8815534-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3109317-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2439534-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7771932-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013539977-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012046139-A1 |
| priorityDate |
2004-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |